Mid-cap biotechs join Trump’s latest round of drug pricing deals
Source: BioPharma Dive - Latest News
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.